The addition of ASA and low-dose IL-2 to an OCDC-Bev-Cy combinatorial regimen prolongs survival and enhanced tumor infiltration of cytolytic CD3+ and CD8+ T cells in an OC mouse model. The gene discussed is IL2; the disease is neoplasm.